Key result
Concurrent COVID-19 infection is linked to ~530% higher in-hospital mortality during acute heart failure hospitalization.
Why the study?
Heart failure exacerbations cause significant morbidity and mortality, but large-scale studies assessing outcomes in the setting of concurrent COVID-19 infection are limited.
Does concurrent COVID-19 infection increase in-hospital mortality in patients hospitalized with acute heart failure exacerbation?
Cohort (n=2,101,980)
Yes
Does concurrent COVID-19 infection increase in-hospital mortality in patients hospitalized with acute heart failure exacerbation?
Concurrent COVID-19 infection in patients hospitalized with acute heart failure exacerbation is associated with a more than six-fold increase in the odds of in-hospital mortality.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to markedly higher mortality with concurrent COVID-19 in acute HF; leaves open whether targeted interventions modify risk.
Heart failure exacerbations impart significant morbidity and mortality, however, large- scale studies assessing outcomes in the setting of concurrent coronavirus disease-19 (COVID-19) are limited. We utilized National Inpatient Sample (NIS) database to compare clinical outcomes in patients admitted with acute congestive heart failure exacerbation (CHF) with and without COVID-19 infection. A total of 2,101,980 patients (Acute CHF without COVID-19 (n = 2,026,765 (96.4%) and acute CHF with COVID-19 (n = 75,215, 3.6%)) were identified. Multivariate logistic regression analysis was utilized to compared outcomes and were adjusted for age, sex, race, income level, insurance status, discharge quarter, Elixhauser co-morbidities, hospital location, teaching status and bed size. Patients with acute CHF and COVID-19 had higher in-hospital mortality compared to patients with acute CHF alone (25.78% vs. 5.47%, adjust OR (aOR) 6.3 (95% CI 6.05–6.62, p < 0.001)) and higher rates of vasopressor use (4.87% vs. 2.54%, aOR 2.06 (95% CI 1.86–2.27, p < 0.001), mechanical ventilation (31.26% vs. 17.14%, aOR 2.3 (95% CI 2.25–2.44, p < 0.001)), sudden cardiac arrest (5.73% vs. 2.88%, aOR 1.95 (95% CI 1.79–2.12, p < 0.001)), and acute kidney injury requiring hemodialysis (5.56% vs. 2.94%, aOR 1.92 (95% CI 1.77–2.09, p < 0.001)). Moreover, patients with heart failure with reduced ejection fraction had higher rates of in-hospital mortality (26.87% vs. 24.5%, adjusted OR 1.26 (95% CI 1.16–1.36, p < 0.001)) with increased incidence of vasopressor use, sudden cardiac arrest, and cardiogenic shock as compared to patients with heart failure with preserved ejection fraction. Furthermore, elderly patients and patients with African-American and Hispanic descents had higher in-hospital mortality. Acute CHF with COVID-19 is associated with higher in-hospital mortality, vasopressor use, mechanical ventilation, and end organ dysfunction such as kidney failure and cardiac arrest.
No takes yet. Share an insight, caveat, or question.
Nasrullah et al. (2023) conducted a cohort in Acute congestive heart failure exacerbation (n=2,101,980). COVID-19 infection vs. Acute heart failure without COVID-19 infection was evaluated on In-hospital mortality (aOR 6.3, 95% CI 6.05-6.62, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: